Allergan Loses Another Battle, But War To Block Restasis Generics Continues
US FDA rejects Allergan's third citizen petition seeking to require comparative clinical trials of generic versions of its dry eye medicine; company appeals patent invalidity ruling and PTAB admonishes Mohawk Tribe for its actions in IPR proceeding.
You may also be interested in...
Mohawk Tribe Questions Patent Board's Impartiality In Restasis Case
Supreme Court's concern about 'panel stacking' reflected in Mohawk Tribe's request to know the identity of PTAB members deciding its request to toss inter partes review.
Allergan May Rue Mohawk Tribe Deal As Court Invalidates Restasis Patents
District court questions legitimacy of Allergan's patent transfer tactic, saying it 'could spell the end of the PTO's IPR program.'
Biosimilar Litigation: Genentech Avastin Suit Tossed; Janssen Remicade Case Uncertain
US court dismisses Genentech suit over Amgen's patent dance moves; Janssen v. Celltrion trial is postponed as parties fight over Janssen's standing to sue; and Amgen wants to bar AbbVie citizen petition filers from seeing its Amjevita information.